Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
What enlightenment has the development of lung cancer bone metastasis brought in the last 22 years
Yi Chen, Xiao-Song Chen, Rong-Quan He, Zhi-Guang Huang, Hui-Ping Lu, Hong Huang, Da-Ping Yang, Zhong-Qing Tang, Xia Yang, Han-Jie Zhang, Ning Qv, Jin-Liang Kong, Gang Chen
Yi Chen, Xiao-Song Chen, Zhi-Guang Huang, Hui-Ping Lu, Xia Yang, Han-Jie Zhang, Ning Qv, Gang Chen, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Rong-Quan He, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Hong Huang, Jin-Liang Kong, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Da-Ping Yang, Department of Pathology, Guigang People’s Hospital of Guangxi/The Eighth Affiliated Hospital of Guangxi Medical University, Guigang 537100, Guangxi Zhuang Autonomous Region, China
Zhong-Qing Tang, Department of Pathology, Wuzhou Gongren Hospital/The Seventh Affiliated Hospital of Guangxi Medical University, Wuzhou 543000, Guangxi Zhuang Autonomous Region, China
Co-first authors: Yi Chen and Xiao-Song Chen.
Co-corresponding authors: Jin-Liang Kong and Gang Chen.
Author contributions: He RQ, Huang ZG, Lu HP, Huang H, Yang DP, Tang ZQ, Yang X, Zhang HJ, Kong JL, and Chen G contributed to designing topics, guiding literature information extraction, guiding statistical analysis, and revising papers; Chen Y, Chen XS and Qv N contributed to literature downloads, information collection, statistical analysis, chart making, and draft paper writing; and all authors commented on previous versions of the manuscript. Chen Y and Chen XS contributed equally to this study, and share joint first authorship. Both Kong JL and Chen G give detailed guidance to this paper, which is of great significance. Therefore, they are both co-corresponding authors. All authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Gang Chen, MD, PhD, Doctor, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. chen_gang_triones@163.com
Received: February 4, 2024
Revised: May 1, 2024
Accepted: May 22, 2024
Published online: June 24, 2024
Processing time: 141 Days and 7.5 Hours
BACKGROUND
Lung cancer bone metastasis (LCBM) is a disease with a poor prognosis, high risk and large patient population. Although considerable scientific output has accumulated on LCBM, problems have emerged, such as confusing research structures.
AIM
To organize the research frontiers and body of knowledge of the studies on LCBM from the last 22 years according to their basic research and translation, clinical treatment, and clinical diagnosis to provide a reference for the development of new LCBM clinical and basic research.
METHODS
We used tools, including R, VOSviewer and CiteSpace software, to measure and visualize the keywords and other metrics of 1903 articles from the Web of Science Core Collection. We also performed enrichment and protein-protein interaction analyses of gene expression datasets from LCBM cases worldwide.
RESULTS
Research on LCBM has received extensive attention from scholars worldwide over the last 20 years. Targeted therapies and immunotherapies have evolved into the mainstream basic and clinical research directions. The basic aspects of drug resistance mechanisms and parathyroid hormone-related protein may provide new ideas for mechanistic study and improvements in LCBM prognosis. The produced molecular map showed that ribosomes and focal adhesion are possible pathways that promote LCBM occurrence.
CONCLUSION
Novel therapies for LCBM face animal testing and drug resistance issues. Future focus should centre on advancing clinical therapies and researching drug resistance mechanisms and ribosome-related pathways.
Core Tip: A comprehensive analysis of 1903 publications from 2000 to 2022 was conducted to identify trends in lung cancer bone metastasis (LCBM) research. The literature on LCBM was systematically organized and analysed according to the changing trends in the knowledge volume, distribution of countries/regions, evolution of research topics and co-occurrence of keywords. The results show that immunotherapy and targeted therapy are new research hotspots and ribosome-related genes play an important role in LCBM. This study also preliminarily explored the potential molecular biological mechanisms of LCBM, which mainly involved ribosome and focal adhesion pathways.
